NCT07581587Recruiting
Investigation of the Effect of Inspiratory Muscle Training and Dual-Task Inspiratory Muscle Training on Cognitive Functions in Heart Failure
Source: ClinicalTrials.gov · Last updated 30 Jul 2026
Brief summary (registry, in English)
The goal of this clinical trial is to evaluate whether dual-task inspiratory muscle training (IMT) is effective in improving cognitive and functional outcomes in adults with heart failure. It will also assess the effects of standard IMT and compare both approaches. The main questions it aims to answer are: * Does dual-task IMT improve cognitive function more than standard IMT or no intervention? * Does dual-task IMT improve respiratory function, inspiratory muscle strength, and exercise capacity? * What are the effects of dual-task IMT on symptoms such as dyspnea and fatigue, and on quality of life, anxiety, and depression? Dual-task IMT, standard IMT, and a control group (no additional intervention) will be compared to determine which approach is more effective in patients with heart failure (HF). Participants will: * Be randomly assigned to one of three groups: dual-task IMT, standard IMT, or control * Perform IMT training 5 days per week for 8 weeks (2 sessions per day, 15 minutes each) if assigned to an intervention group * Complete 1 supervised in-person session per week and 4 sessions via telerehabilitation if assigned to an intervention group * Undergo assessments before and after the 8-week intervention, including cognitive tests, respiratory function, exercise capacity, and symptom evaluations
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 54 (estimated)
- First submitted
- 17 Apr 2026
- Start date
- 27 Jul 2026
- Primary completion date
- Jul 2027
- Lead sponsor
- Istanbul University - Cerrahpasa
- Diseases
- Heart failure
- NCT number
- NCT07581587
What you commit to
- Study type: Interventional
- Planned participants: 54
- From 27 Jul 2026 to the primary completion date, Jul 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Diagnosis of any neurological or neurodegenerative disease (e.g., Parkinson's disease, stroke, dementia, Alzheimer's disease)
- Diagnosis of pulmonary disease (e.g., chronic obstructive pulmonary disease, obstructive sleep apnea)
- Myocardial infarction within the last 6 months
- Uncontrolled hypertension and/or diabetes mellitus
- Severe valvular heart disease and/or uncontrolled arrhythmias
Other
- Orthopedic, visual, or hearing impairments that may prevent independent test completion
- Inability to comply with study procedures or follow instructions
Who the study is looking for
- Age ≥ 40 years
- Diagnosed with HF with reduced ejection fraction (HFrEF) according to the 2023 ESC HF Guidelines
- Classified as NYHA functional class I-III
- Clinically stable for at least 3 months and receiving stable pharmacological treatment
- Able to read and understand Turkish
- MoCA score ≥ 21
- Willingness to participate and provide written informed consent
Age in the registry: 40 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Istanbul University-Cerrahpaşa, Cardiology Institute Coordinator of this site? Confirm its status | Istanbul | Turkey (Türkiye) | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.